34 molecules on this site have a full explanation and no product beside them — and for two different reasons. Some have a regulatory record, and the record is the reason. The rest we simply do not track and do not offer. Both are worth saying out loud, and they are not the same sentence.
For these, FDA has said something we can cite, and what it said is why there is nothing to buy here. We print the status verbatim. Where the status is our own forecast rather than an FDA determination, we say so on the row — a projection in a regulatory field is still a projection, and you should be able to tell the difference at a glance.
A growth-hormone-releasing peptide usually stacked with Ipamorelin, but non-compoundable in the US.
Nomination withdrawn · in no FDA category
Not Category 2. CJC-1295's nomination was withdrawn by the nominator, so it sits in FDA's withdrawn-nominations table and in no category — outside every enforcement-discretion policy. FDA did not re-evaluate it and preserved its safety-risk description verbatim.
A second-generation GH-releasing peptide, more selective than GHRP-6 but still restricted and research-only.
Expected to stay restricted
FDA has published no present-tense determination for this substance. This is our projection, not a finding.
A first-generation GH-releasing peptide that strongly stimulates appetite as well as GH, restricted and research-only.
Expected to stay restricted
FDA has published no present-tense determination for this substance. This is our projection, not a finding.
A selective growth-hormone secretagogue, the usual partner to CJC-1295, also non-compoundable in the US.
Withdrawn (503A) · Category 2 (503B interim policy)
Pathway-specific, and it must stay that way: Ipamorelin acetate is in FDA's withdrawn-nominations table on the 503A side, while FDA still annotates it as Category 2 under the 503B interim policy. Never state either half globally.
An orally-active growth-hormone secretagogue, not a peptide, studied for GH/IGF-1 and appetite.
Category 2 (interim 503A policy) · may present significant safety risks
Named on FDA's current Category 2 list as ibutamoren mesylate. Reviewed at the October 29, 2024 PCAC, where FDA recommended against inclusion in the 503A Bulks Regulation. The substance stayed in Category 2 and no rulemaking followed. Not a peptide.
A peptide that raises sexual desire by acting on the brain's arousal pathways, not blood flow.
FDA-approved product FDA-approved as Vyleesi (bremelanotide) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 is not the approved product and is not FDA-approved.
Restricted
The record carries this status without naming an issuing authority. We print it as it stands rather than attribute it to an agency that has not said it.
A natural cathelicidin antimicrobial and immune-signaling peptide, restricted, and pro-inflammatory in the wrong context.
Expected to stay restricted
FDA has published no present-tense determination for this substance. This is our projection, not a finding.
An immune-modulating peptide, studied for immune support.
Nomination withdrawn · in no FDA category · FDA advised against 503A listing (Dec 2024 PCAC)
Not Category 2. The nomination was withdrawn by the nominator and the substance was removed from Category 2 effective September 27, 2024, leaving it in FDA's withdrawn-nominations table and in no category at all. FDA elected to proceed with the presentation regardless: thymosin alpha-1 (free base and acetate) was reviewed at the December 4, 2024 PCAC, where FDA's position was that it should not be included on the 503A Bulks List. Approval in other countries (thymalfasin / Zadaxin) is not a US regulatory status and is never stated as one.
A reproductive-hormone signaling peptide studied for libido and fertility pathways.
Category 2 (interim 503A policy) · may present significant safety risks
Named on FDA's current Category 2 list as kisspeptin-10. Reviewed at the October 29, 2024 PCAC, where FDA recommended against inclusion in the 503A Bulks Regulation. The substance stayed in Category 2 and no rulemaking followed.
A mechano-growth-factor splice variant of IGF-1 used for local muscle repair, research-only, restricted.
Expected to stay restricted
FDA has published no present-tense determination for this substance. This is our projection, not a finding.
One further molecule carries a not-available verdict and has no monograph yet, so it is not listed here. We would rather leave the row out than write a description nobody has reviewed.
We wrote the full explanation because people ask. We do not track these for regulatory status — there is no active compounding process to follow — and we do not offer them. Where the record names an approved product, the row names it too; where the row is silent, that is a gap in our record and never a statement that no approval exists. That an approval exists and that we do not offer the molecule are two separate facts, and we will not let one imply the other.
An investigational non-peptide, small-molecule oral GLP-1 agonist, 'GLP-1 in a daily pill.'
A potent ghrelin-receptor GH-releasing peptide from the legacy bodybuilding toolkit, restricted, with prolactin and desensitization issues.
A growth-hormone-axis peptide with FDA-approved origins.
FDA-approved product FDA-approved as EGRIFTA (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That is the approved indication; longevity and body-composition use is off-label, and the compounded form is not FDA-approved.
A mitochondrial-DNA-encoded cytoprotective peptide studied in aging and metabolic stress, research-stage.
A topical cosmetic peptide marketed as a 'Botox-like' expression-line softener, low-risk, well-established in skincare.
A porcine-derived neurotrophic peptide preparation with a long clinical heritage in stroke and dementia abroad, the most-evidenced nootropic peptide.
A spadin-derived peptide that blocks the TREK-1 channel, studied preclinically for fast-acting antidepressant effects.
A nootropic peptide studied for calm and anxiety support.
A non-erythropoietic peptide derived from EPO, studied for neuropathic pain and inflammation, some human trial data.
A thymic peptide preparation from the Khavinson school, claimed for immune restoration, limited independent validation.
A short 'bioregulator' peptide from the Russian Khavinson school, claimed for brain and longevity support, thin Western validation.
A Khavinson-school dipeptide 'bioregulator' claimed for immune and longevity support, minimal independent evidence.
An oral medicine, not a peptide, that raises the body's own testosterone, a fertility-sparing alternative to TRT.
The bonding-and-arousal neuropeptide, with off-label intranasal use for intimacy and connection.
FDA-approved product FDA-approved as Pitocin for labor. Intranasal use for intimacy or arousal is off-label, and the compounded form is not FDA-approved.
A long-acting GnRH agonist; the biohacker 'hormone restart' use is off-label and illicit.
FDA-approved product FDA-approved as Trelstar for specific oncology and endocrine indications. The "testosterone restart" use is off-label, unproven, and not offered.
A non-peptide small-molecule NNMT inhibitor marketed for fat-cell metabolism, research-stage only.
A pro-apoptotic peptide that targets the blood supply of fat tissue, striking animal fat loss, but documented kidney toxicity.
A fragment of growth hormone marketed for fat loss, with weak human evidence.
A myostatin-inhibiting protein that can drive extreme muscle growth, high-risk, WADA-banned, research-only.
A senolytic peptide designed to clear senescent ('zombie') cells by triggering their apoptosis, preclinical only.
A long-acting IGF-1 analog used in bodybuilding circles for muscle and recovery, potent, banned in sport, and research-only.
A non-peptide triple-reuptake inhibitor studied as an appetite suppressant, not US-approved, with cardiovascular and psychiatric cautions.
An off-label low dose of an approved drug, not a peptide, used for immune and inflammatory conditions.
A first-line diabetes drug, not a peptide, widely studied as a longevity and metabolic agent.
FDA-approved product FDA-approved as metformin (multiple branded and generic products) for type 2 diabetes. Metabolic and longevity use is off-label and the evidence is still emerging.
A catalogue tells you what it can sell you. A reference tells you what it knows. This page is the part of the Knowledge Base with no commercial upside at all, which is precisely why it is worth publishing — and why nothing on it links to a checkout.
Related: the full Knowledge Base · what we don't know · what the FDA actually says